Trial · NCT07907380
Endoscopic Pituitary Lesions Transnasal Approach and Minimally Invasive Eyebrow Incision Approach
NCT07907380, Completed, Kafrelsheikh University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Endoscopic Pituitary Lesions Transnasal Approach and Minimally Invasive Eyebrow Incision Approach. Trials, record NCT07907380. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907380
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Endoscopic Pituitary Lesions Transnasal Approach and Minimally Invasive Eyebrow Incision Approach
- NCT number
- NCT07907380
- Status
- Completed
- Enrollment
- 60 participants, actual
- Lead sponsor
- Kafrelsheikh University
- Conditions
- Endoscopic Pituitary Transnasal Approach, Minimally Invasive Eyebrow Incision
- Interventions
- Endoscopic Transnasal Approach, Minimally Invasive Eyebrow Approach
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Successful Tumor Resection Rate | 3 months after surgery | Percentage of patients achieving successful tumor resection following endoscopic transnasal surgery or minimally invasive supraorbital eyebrow surgery, assessed using postoperative contrast-enhanced sellar magnetic resonance imaging (MRI). |
| Secondary | Visual Improvement Rate | 3 months after surgery | Percentage of patients with improvement in visual acuity and/or visual fields compared with preoperative findings, based on documented ophthalmological assessments. |
| Secondary | Endocrinological Improvement Rate | 3 months after surgery | Percentage of patients with improvement of preoperative hormonal abnormalities, assessed using documented postoperative hormonal investigations and endocrinological assessments. Criteria for improvement and remission will be specified for each hormonal disorder. |
| Secondary | Estimated Intraoperative Blood Loss | Intraoperatively | Estimated volume of blood lost during surgery was expressed in milliliters and recorded. |
| Secondary | Degree of pain | 3 months after surgery | Degree of pain was assessed using documented Visual Analog Scale scores ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity. |
| Secondary | Incidence of Postoperative Hemorrhage | 3 months after surgery | Percentage of patients with postoperative hemorrhage was documented. |
| Secondary | Incidence of Postoperative Wound Complications | 3 months after surgery | Incidence of postoperative wound complications were recorded. |
| Secondary | Incidence of Residual Tumor | 3 months after surgery | Percentage of patients with residual tumor identified on postoperative contrast-enhanced sellar magnetic resonance imaging. |
| Secondary | Incidence of Tumor Recurrence | 3 months after surgery | Percentage of patients with reappearance of tumor on follow-up contrast-enhanced sellar magnetic resonance imaging after previously documented complete resection. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907380
GET https://conductscience.org/api/trials/v1/NCT07907380/registered